Jazz Pharmaceuticals Q2 2026: Revenue Beats by $90M as Zepzelca Growth Offsets LAGOON Setback
JAZZ has more than doubled off its 52-week low of $105.
Summary
Jazz Pharmaceuticals reported Q2 2026 revenue of $1.21B, beating estimates by $90M, with net income of $192.8M. Zepzelca's first-line maintenance launch drove 42% growth, but the LAGOON trial failure will lead to withdrawal of the second-line indication. Ziihera's first-line GEA sBLA has an August 25 PDUFA date.
Updates
· Reuters — Jazz raised full-year 2026 revenue guidance to $4.60-$4.75B. Xywav added 525 net patients and Epidiolex grew 16%.
Key Events · Earnings and Guidance · JAZZ
-
Q2 Revenue Beat
Total revenues of $1.21B exceeded consensus by $90M, driven by 42% growth in Zepzelca to $105.8M following its first-line maintenance launch.
-
Net Income Swing
Net income of $192.8M compared to a loss of $718.5M in Q2 2025, reflecting revenue growth and absence of prior-year Chimerix acquisition IPR&D charge.
-
Zepzelca LAGOON Failure
The Phase 3 LAGOON trial did not meet its primary OS endpoint; Jazz will submit a labeling supplement to remove the second-line SCLC indication, though the first-line maintenance indication is unaffected.
-
Ziihera sBLA Accepted
FDA accepted the sBLA for Ziihera in first-line HER2-positive GEA with Priority Review and a PDUFA target action date of August 25, 2026.
Analysis · JAZZ · Life Sciences
A strong second quarter saw revenue reach $1.21B, beating consensus by $90M, fueled by a 42% surge in Zepzelca following its first-line maintenance approval. Net income swung to $192.8M from a loss of $718.5M a year ago. However, the LAGOON confirmatory trial for Zepzelca in second-line SCLC failed to meet its primary OS endpoint, and the company will withdraw that indication — a setback that partially tempers the commercial momentum. On the pipeline front, the sBLA for Ziihera in first-line GEA was accepted with an August 25, 2026 PDUFA date, representing a near-term catalyst. The balance sheet strengthened with the repayment of $1.0B in 2026 Notes, though the 2030 Notes are now exchangeable, creating potential near-term dilution overhang.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAZZ was trading at $260.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8B. The 52-week trading range was $105.00 to $261.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.